Skip to content
NewA calmer, faster ZeroHour

Isomorphic Labs raises $5 billion to advance AI drug candidates

Original title: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

TechCrunch · AIby Ram Iyer ()1 min read1
Part of a story covered by 2 sourcesIsomorphic Labs raises $5 billion to move drugs toward trialsMerged summary & timeline
AI summary · x-ai/grok-4.7Summaries by Vani AI

The Series C, co-led by Greenoaks and Sequoia, follows a $2.1 billion round in May; valuation was not disclosed.

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, raised $5 billion in a Series C to move candidates toward clinical trials. Greenoaks and Sequoia Capital co-led, with Andreessen Horowitz joining existing backers including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The company cites positive preclinical results in oncology and immunology and existing deals with Eli Lilly, Novartis, and Johnson & Johnson. Funds will expand its simulation-based drug-design engine, which builds on AlphaFold.

Unconfirmed: A $50 billion valuation is only what Bloomberg reported the lab was seeking; Isomorphic did not confirm it.

Key facts
  • Founder Demis Hassabis left as DeepMind head and became DeepMind chairman.
  • Hassabis and John Jumper won the chemistry Nobel for AlphaFold.
  • Bloomberg earlier reported a target valuation of $50 billion.
  • The company did not disclose the new valuation.
Explain this AI news with Vani AIWhat was announced, what is new and why it matters, in a new chat

From the original article

1 min read at techcrunch.com

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

TechCrunch · AI

By Ram Iyer · techcrunch.com

Read the full article at TechCrunch · AI

A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.